{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:17:22Z","timestamp":1788247042848,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI17C2206"],"award-info":[{"award-number":["HI17C2206"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2022-KH129295"],"award-info":[{"award-number":["RS-2022-KH129295"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["RS-2022-CC125163"],"award-info":[{"award-number":["RS-2022-CC125163"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"KHIDI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.esmoop.2026.107706","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:57:32Z","timestamp":1783601852000},"page":"107706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5650-1224","authenticated-orcid":false,"given":"J.W.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9665-062X","authenticated-orcid":false,"given":"S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.K.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-3620","authenticated-orcid":false,"given":"J.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-3240","authenticated-orcid":false,"given":"K.-H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4334-4028","authenticated-orcid":false,"given":"M.J.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7894-8772","authenticated-orcid":false,"given":"I.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.s.","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.U.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9766-1531","authenticated-orcid":false,"given":"J.E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-5507","authenticated-orcid":false,"given":"J.H.","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5965-3204","authenticated-orcid":false,"given":"J.H.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2464-7920","authenticated-orcid":false,"given":"K.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.107706_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000055396","article-title":"Biology of HER2 and its importance in breast cancer","volume":"61","author":"Yarden","year":"2001","journal-title":"Oncology"},{"issue":"16","key":"10.1016\/j.esmoop.2026.107706_bib2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107706_bib3","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107706_bib4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Eng J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107706_bib5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Eng J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107706_bib6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"Nahta","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107706_bib7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.breast.2015.06.002","article-title":"Potential of overcoming resistance to HER2-targeted therapies through the PI3K\/Akt\/mTOR pathway","volume":"24","author":"Wilks","year":"2015","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107706_bib8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4143\/crt.2022.221","article-title":"PIK3CA mutation is associated with poor response to HER2-targeted therapy in breast cancer patients","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2026.107706_bib9","article-title":"Comparison of PIK3CA mutation prevalence in breast cancer across predicted ancestry populations","volume":"6","author":"Chen","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.107706_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101738","article-title":"Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: a meta-analysis and bioinformatic analysis of TCGA-BRCA data","volume":"37","author":"Chen","year":"2023","journal-title":"Transl Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2026.107706_bib11","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2026.107706_bib12","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.107706_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41523-024-00648-0","article-title":"Gedatolisib shows superior potency and efficacy versus single-node PI3K\/AKT\/mTOR inhibitors in breast cancer models","volume":"10","author":"Rossetti","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2026.107706_bib14","series-title":"Gedatolisib plus fulvestrant \u00b1 palbociclib in HR+\/HER2\u2013\/PIK3CA WT ABC: first results from VIKTORIA-1","author":"Hurvitz","year":"2025"},{"issue":"31","key":"10.1016\/j.esmoop.2026.107706_bib15","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107706_bib16","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4143\/crt.2023.1294","article-title":"Analytical and clinical validation of a highly sensitive NGS-based ctDNA assay with real-world concordance in non-small cell lung cancer","volume":"56","author":"Yi","year":"2024","journal-title":"Cancer Res Treat"},{"issue":"17","key":"10.1016\/j.esmoop.2026.107706_bib17","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107706_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3601","article-title":"Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells","volume":"16","author":"Rexer","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107706_bib19","first-page":"3067","article-title":"PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations","volume":"12","author":"Chung","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.esmoop.2026.107706_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1108242","article-title":"The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+\/PIK3CA mutant breast cancer","volume":"13","author":"Cataldo","year":"2023","journal-title":"Front Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2026.107706_bib21","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2013.54.5384","article-title":"Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer","volume":"32","author":"Baselga","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2026.107706_bib22","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-15-2499","article-title":"Relationship between tumor biomarkers and efficacy in EMILIA: a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer","volume":"22","author":"Baselga","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.esmoop.2026.107706_bib23","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1158\/1078-0432.CCR-24-0459","article-title":"An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in patients with breast cancer from four prospective clinical trials","volume":"30","author":"Jank","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107706_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.48814","article-title":"Association of PIK3CA mutation with pathologic complete response and outcome by hormone receptor status and intrinsic subtype in early-stage ERBB2\/HER2-positive breast cancer","volume":"6","author":"Zagami","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107706_bib25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","article-title":"Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Andr\u00e9","year":"2014","journal-title":"Lancet Oncol"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2026.107706_bib26","article-title":"Alpelisib in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2+, PIK3CA-mutant advanced breast cancer: EPIK-B2 Study Part 1 safety and efficacy results","volume":"83","author":"Hurvitz","year":"2023","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107706_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2023.04.516","article-title":"Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1016\/j.esmoop.2026.108527","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:21:20Z","timestamp":1784546480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926016480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2059702926016480"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107706","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107706"}}